Market News
3 min read | Updated on February 03, 2025, 14:32 IST
SUMMARY
Dr Agarwal's Health Care IPO allotment status will be finalised on Monday. Investors can visit KFin Technologies, the NSE, and the BSE portals to track bid finalisation status.
Dr Agarwal's Health Care shares will be listed on the NSE and the BSE on Wednesday, February 5, at 10 am. | Image: Shutterstock
Dr Agarwal's Health Care IPO allotment: The basis of allotment of Dr Agarwal's Health Care IPO will be finalised on Monday, February 3. The initial public offer was fully subscribed on the final day of subscription on January 31.
As per the consolidated data on the National Stock Exchange (NSE), the initial share sale received bids for 8,32,18,380 shares against 5,35,26,172 equity shares on offer, translating to a total subscription of 1.55 times.
Qualified institutional buyers (QIBs) led the bidding as they subscribed to their category 4.64 times. They applied for 6,73,61,280 shares against 1,45,19,200 set aside for them.
The non-institutional investors (NIIs) quota was booked 40% as they submitted applications for 43,07,310 shares compared to 1,08,89,400 shares on offer.
The retail individual investors (RIIs) applied to 1,05,40,285 shares against 2,54,08,599 shares reserved for them, leading to a 41% subscription.
The employees part was subscribed just 27% as they bid for 4,25,565 compared to 15,79,399 on offer.
Dr Agarwal's Health Care shares will be listed on the National Stock Exchange (NSE) and the BSE on Wednesday, February 5, at 10 am.
The ₹3,027.26-crore IPO was a ₹300 crore worth fresh issue and an offer-for-sale valued at ₹2,727.26 crore. The price band was fixed at ₹382-₹402 per equity share.
Investors were allowed to apply for at least one lot consisting of 35 shares. The minimum investor was ₹14,070.
Dr Agarwal's Health Care provides various services, such as refractive, cataract, and other surgeries, non-surgical treatments, diagnosis, and the sale of optical products.
Kotak Mahindra Capital Company, Jefferies India, Motilal Oswal Investment Advisors, and Morgan Stanley India Company are the issue's book-running lead managers.
Particulars | FY22 | FY23 | FY24 | H1FY25 |
---|---|---|---|---|
Revenue | ₹696.08 cr | ₹1,017.98 cr | ₹1,332.15 cr | ₹820.06 cr |
Net Profit | ₹43.16 cr | ₹103.23 cr | ₹95.05 cr | ₹39.56 cr |
Related News
About The Author
Next Story